450 related articles for article (PubMed ID: 28222336)
101. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes.
Lieu YK; Liu Z; Ali AM; Wei X; Penson A; Zhang J; An X; Rabadan R; Raza A; Manley JL; Mukherjee S
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34930825
[TBL] [Abstract][Full Text] [Related]
102. [Biology of sideroblastic anemia].
Harigae H
Rinsho Ketsueki; 2017; 58(4):347-352. PubMed ID: 28484165
[TBL] [Abstract][Full Text] [Related]
103. Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS).
Ohba R; Furuyama K; Yoshida K; Fujiwara T; Fukuhara N; Onishi Y; Manabe A; Ito E; Ozawa K; Kojima S; Ogawa S; Harigae H
Ann Hematol; 2013 Jan; 92(1):1-9. PubMed ID: 22983749
[TBL] [Abstract][Full Text] [Related]
104. Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Edahiro Y; Ochiai T; Hashimoto Y; Morishita S; Shirane S; Inano T; Furuya C; Koike M; Noguchi M; Usuki K; Shiratsuchi M; Nakajima K; Ohtsuka E; Tanaka H; Kawata E; Nakamae M; Ueda Y; Aota Y; Sugita Y; Ohara S; Yamasaki S; Asagoe K; Yoshida S; Yamanouchi J; Suzuki S; Kondo T; Kanisawa Y; Toyama K; Omura H; Mizuchi D; Sakamaki S; Ando M; Komatsu N
Int J Hematol; 2023 Jul; 118(1):47-53. PubMed ID: 37058247
[TBL] [Abstract][Full Text] [Related]
105. MDS/MPN-RS-T justified inclusion as a unique disease entity?
Montalban-Bravo G; Garcia-Manero G
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101147. PubMed ID: 32460979
[TBL] [Abstract][Full Text] [Related]
106. Mechanistic Insights of Aberrant Splicing with Splicing Factor Mutations Found in Myelodysplastic Syndromes.
Kataoka N; Matsumoto E; Masaki S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360561
[TBL] [Abstract][Full Text] [Related]
107. Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.
Gelsi-Boyer V; Cervera N; Bertucci F; Brecqueville M; Finetti P; Murati A; Arnoulet C; Mozziconacci MJ; Mills KI; Cross NC; Vey N; Birnbaum D
Haematologica; 2013 Apr; 98(4):576-83. PubMed ID: 23065512
[TBL] [Abstract][Full Text] [Related]
108. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.
Lee SC; Dvinge H; Kim E; Cho H; Micol JB; Chung YR; Durham BH; Yoshimi A; Kim YJ; Thomas M; Lobry C; Chen CW; Pastore A; Taylor J; Wang X; Krivtsov A; Armstrong SA; Palacino J; Buonamici S; Smith PG; Bradley RK; Abdel-Wahab O
Nat Med; 2016 Jun; 22(6):672-8. PubMed ID: 27135740
[TBL] [Abstract][Full Text] [Related]
109. Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.
Moura PL; Mortera-Blanco T; Hofman IJ; Todisco G; Kretzschmar WW; Björklund AC; Creignou M; Hagemann-Jensen M; Ziegenhain C; Cabrerizo Granados D; Barbosa I; Walldin G; Jansson M; Ashley N; Mead AJ; Lundin V; Dimitriou M; Yoshizato T; Woll PS; Ogawa S; Sandberg R; Jacobsen SEW; Hellström-Lindberg E
Cancer Res; 2024 Jan; 84(2):211-225. PubMed ID: 37921711
[TBL] [Abstract][Full Text] [Related]
110. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
Venable ER; Chen D; Chen CP; Bessonen KR; Nguyen PL; Oliveira JL; Reichard KK; Hoyer JD; Althoff SD; Roh DJ; Miller MA; Begna K; Patnaik MM; Litzow MR; Al-Kali A; Viswanatha DS; He R
Am J Clin Pathol; 2021 Sep; 156(4):679-690. PubMed ID: 33978189
[TBL] [Abstract][Full Text] [Related]
111. Myelodysplastic Syndrome Updated.
Hasserjian RP
Pathobiology; 2019; 86(1):7-13. PubMed ID: 30041243
[TBL] [Abstract][Full Text] [Related]
112. [Role of Aberrant Splicing in Pathogenesis of Myelodysplastic Syndromes-Review].
Li L; Xiao ZJ; Sun XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):617-621. PubMed ID: 28446323
[TBL] [Abstract][Full Text] [Related]
113. A variant erythroferrone disrupts iron homeostasis in
Bondu S; Alary AS; Lefèvre C; Houy A; Jung G; Lefebvre T; Rombaut D; Boussaid I; Bousta A; Guillonneau F; Perrier P; Alsafadi S; Wassef M; Margueron R; Rousseau A; Droin N; Cagnard N; Kaltenbach S; Winter S; Kubasch AS; Bouscary D; Santini V; Toma A; Hunault M; Stamatoullas A; Gyan E; Cluzeau T; Platzbecker U; Adès L; Puy H; Stern MH; Karim Z; Mayeux P; Nemeth E; Park S; Ganz T; Kautz L; Kosmider O; Fontenay M
Sci Transl Med; 2019 Jul; 11(500):. PubMed ID: 31292266
[TBL] [Abstract][Full Text] [Related]
114. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
115. Analysis of gene mutation characteristics and its correlation with prognosis in patients with myelodysplastic syndromes.
Yang X; Zhao H; Wu H; Guo X; Jia H; Liu W; Wei Y; Can C; Ma D
Clin Chim Acta; 2024 Feb; 554():117789. PubMed ID: 38246208
[TBL] [Abstract][Full Text] [Related]
116. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.
Zhang Q; Haider M; Al Ali NH; Lancet JE; Epling-Burnette PK; List AF; Padron E; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):400-406.e2. PubMed ID: 32179032
[TBL] [Abstract][Full Text] [Related]
117. SF3B1 deficiency impairs human erythropoiesis via activation of p53 pathway: implications for understanding of ineffective erythropoiesis in MDS.
Huang Y; Hale J; Wang Y; Li W; Zhang S; Zhang J; Zhao H; Guo X; Liu J; Yan H; Yazdanbakhsh K; Huang G; Hillyer CD; Mohandas N; Chen L; Sun L; An X
J Hematol Oncol; 2018 Feb; 11(1):19. PubMed ID: 29433555
[TBL] [Abstract][Full Text] [Related]
118. The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations.
Chen L; Chen JY; Huang YJ; Gu Y; Qiu J; Qian H; Shao C; Zhang X; Hu J; Li H; He S; Zhou Y; Abdel-Wahab O; Zhang DE; Fu XD
Mol Cell; 2018 Feb; 69(3):412-425.e6. PubMed ID: 29395063
[TBL] [Abstract][Full Text] [Related]
119. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.
Shirai CL; White BS; Tripathi M; Tapia R; Ley JN; Ndonwi M; Kim S; Shao J; Carver A; Saez B; Fulton RS; Fronick C; O'Laughlin M; Lagisetti C; Webb TR; Graubert TA; Walter MJ
Nat Commun; 2017 Jan; 8():14060. PubMed ID: 28067246
[TBL] [Abstract][Full Text] [Related]
120. Validation of the WHO 2016 proposals for Myelodysplastic syndromes patients with the presence of ring sideroblasts but without excess blasts.
Li Y; Cui R; Qin T; Xu Z; Zhang Y; Cai W; Cui W; Liu J; Li B; Xiao Z
Br J Haematol; 2017 Sep; 178(5):813-816. PubMed ID: 27292319
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
